Psyched Wellness Ltd (CSE:PSYC) (OTCQB:PSYCF) (FRA:5U9) CEO Jeff Stevens tells Proactive it has kicked off its next preclinical study of AME-1, its proprietary Amanita muscaria extract.
Stevens says the 90-day oral toxicity study is 'big turning point' for the company, as once results are received for both its 14-day and 90-day study, the specific dose range will allow it to move to the next phase of looking at product formulation.